1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
J. Capdevila Castillón, M. Plana, B. Castelo, L. Iglesias, J. Hernando, R. Yaya Tur, N. Baste, A. Carmona-Bayonas, S. Ruiz, J. Trigo, Isabel LORENZO‐LORENZO, E. Grande, D. Lorente, L. Ugidos, G. Marquina, A. García-Alvarez, M. Taberna, J. Villamayor, Javier Molina‐Cerrillo, T. Alonso-Gordoa
Topics & Concepts
DurvalumabMedicineTremelimumabRefractory (planetary science)OncologyInternal medicineThyroid cancerThyroid carcinomaCarcinomaThyroidCancerImmunotherapyNivolumabIpilimumabAstrobiologyPhysicsThyroid Cancer Diagnosis and Treatment